☆ 4.6 Review

A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer

Ayumu Yoshikawa et al.

Summary: Human epidermal growth factor receptor 2 (HER2) amplification is a biomarker in colorectal cancer (CRC) that occurs in 1-4% of metastatic CRC (mCRC). Next-generation sequencing-based analysis is used to identify HER2 amplification and assess HER2 overexpression. Clinical trials have demonstrated the efficacy of HER2-targeted therapies in HER2-positive mCRC. The review discusses the molecular basis of HER2-targeted therapeutic strategies for patients with HER2-positive mCRC.

CANCERS (2023)

Add to Collection

Article Oncology

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Van K. Morris et al.

Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

HER2 targeted therapy in colorectal cancer: New horizons

Ali Abdulnabi Suwaidan et al.

Summary: This article provides an overview of the clinicopathological features of HER2 amplification and mutations in metastatic colorectal cancer (mCRC), and its role as a biomarker of anti-EGFR resistance. The review also discusses the preclinical, clinical, and translational studies investigating the use of HER2 targeted therapies and future research.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade

Zhaohui Jin et al.

Summary: Immunotherapy with immune checkpoint inhibitors (ICIs) has transformed the treatment of colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) by producing frequent and durable responses. However, resistance mechanisms and biomarkers to identify resistant patients are still needed. Understanding these mechanisms may lead to the development of novel strategies to overcome resistance and broaden the benefit of ICIs.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

Takayuki Yoshino et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Chemistry, Physical

Somatic cell-derived organoids as prototypes of human epithelial tissues and diseases

Masayuki Fujii et al.

Summary: This review highlights the approaches used to generate somatic cell-derived organoids for modeling epithelial tissue and understanding disease progression. It discusses how advancements in understanding the regulation of epithelial tissue stem cells have led to the development of organoids, which retain the characteristics of their tissue of origin. Additionally, it mentions the growing effort in using organoids to model human diseases and their contributions to understanding disease biology.

NATURE MATERIALS (2021)

Add to Collection

Article Oncology

Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis

Mariana I. Chavez et al.

Summary: This study is the largest TSH series in the US and demonstrates evidence of safety and feasibility in the management of bilateral CRLM. Outcomes are influenced by margin status and operative estimated blood loss (EBL).

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

Chao Liu et al.

Summary: IL-17A promotes resistance to anti-PD-1 therapy by increasing PD-L1 expression through the p65/NRF1/miR-15b-5p axis. Blocking IL-17A improves the efficacy of anti-PD-1 therapy in MSS CRC murine models, suggesting IL-17A as a potential therapeutic target to sensitize patients with MSS CRC to ICI therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review

Leah H. Biller et al.

Summary: Colorectal cancer is the third most common cause of cancer mortality worldwide. For patients diagnosed with metastatic colorectal cancer, approximately 70% to 75% can survive beyond 1 year. Tailoring treatments based on the molecular and pathologic features of the tumor has shown to improve overall survival rates.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero et al.

Summary: The study evaluated different treatment regimens for patients with BRAF V600E-mutant metastatic colorectal cancer, showing that encorafenib plus cetuximab improved overall survival, objective response rate, and progression-free survival compared to standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Targeting KRAS in Colorectal Cancer

Chongkai Wang et al.

Summary: Recent research has shown promising antitumor activity of highly potent KRAS(G12C) specific inhibitors in patients with NSCLC and colorectal cancer. Despite encouraging progress, further efforts are needed to identify biomarkers predicting response to KRAS(G12C) inhibition and develop strategies to overcome resistance.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection

Review Oncology

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

A. Grothey et al.

Summary: Colorectal cancer remains a leading cause of cancer-related deaths globally, with the mutation in the BRAF gene, particularly the V600E substitution, affecting 10% of metastatic CRC patients and indicating a poor prognosis. Recent advancements in combination therapies targeting the MAPK pathway have shown promising results in treating BRAF V600E-mutated mCRC patients, offering new hope in the management of this subtype of cancer.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

NTRK fusions in colorectal cancer: clinical meaning and future perspective

Margherita Ratti et al.

Summary: Despite the efforts of the scientific community, the prognosis of metastatic colorectal cancer remains poor. NTRK rearrangements may represent a new therapeutic target for improving outcomes in mCRC. The identification of new molecular biomarkers and the development of new molecular targets could potentially lead to breakthroughs in the treatment of colorectal cancer patients.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

Add to Collection

Article Oncology

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

Dennis Doleschel et al.

Summary: The study showed that the combination therapy of REG and aPD1 significantly improved anti-tumor activity in both colorectal cancer models. The synergistic effects of the two drugs induced sustained M1 polarization and durable reduction of Treg cells, leading to a sustained inhibition of colon cancer regrowth. This suggests the potential for clinical evaluation in colorectal cancer, including MSS tumors.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Oncology

The metabolic landscape of RAS-driven cancers from biology to therapy

Suman Mukhopadhyay et al.

Summary: This review highlights the metabolic reprogramming mediated by oncogenic RAS in cancer and explores the potential novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers. Mukhopadhyay, Vander Heiden, and McCormick provide insights into the metabolic landscape of RAS-driven cancers, the effects of RAS-directed metabolic reprogramming, and opportunities for therapeutic targeting of these cancers.

NATURE CANCER (2021)

Add to Collection

Article Oncology

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Volker Heinemann et al.

Summary: This study found that in patients with RAS wild-type colorectal cancer, FOLFIRI plus cetuximab had a higher objective response rate and longer overall survival compared to FOLFIRI plus bevacizumab. The advantage of cetuximab was mainly observed in patients with left-sided primary tumors.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab

Nayoung Kim et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Comprehensive review of targeted therapy for colorectal cancer

Yuan-Hong Xie et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Oncology

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

S. Stintzing et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

Francesco Caputo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Medicine, General & Internal

Colorectal cancer

Evelien Dekker et al.

LANCET (2019)

Add to Collection

Article Multidisciplinary Sciences

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Daniele V. F. Tauriello et al.

NATURE (2018)

Add to Collection

Review Gastroenterology & Hepatology

Development of Preclinical Models to Understand and Treat Colorectal Cancer

Judith S. Sebolt-Leopold

CLINICS IN COLON AND RECTAL SURGERY (2018)

Add to Collection

Review Medicine, Research & Experimental

An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

Giulia Fornasier et al.

ADVANCES IN THERAPY (2018)

Add to Collection

Article Oncology

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

J. K. Mooi et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Shukui Qin et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Organoids in cancer research

Jarno Drost et al.

NATURE REVIEWS CANCER (2018)

Add to Collection

Article Oncology

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

J. F. Seligmann et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Review Oncology

Models in Translational Oncology: A Public Resource Database for Preclinical Cancer Research

Claudia Galuschka et al.

CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases

Georgios A. Margonis et al.

ANNALS OF SURGICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

C. Bokemeyer et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

David M. Hyman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

RAS Mutations Affect Pattern of Metastatic Spread and Increase Propensity for Brain Metastasis in Colorectal Cancer

Rona Yaeger et al.

CANCER (2015)

Add to Collection

Article Oncology

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolas J. Llosa et al.

CANCER DISCOVERY (2015)

Add to Collection

Article Surgery

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

Jean-Nicolas Vauthey et al.

ANNALS OF SURGERY (2013)

Add to Collection

Article Multidisciplinary Sciences

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Anirudh Prahallad et al.

NATURE (2012)

Add to Collection

Article Oncology

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Ryan B. Corcoran et al.

CANCER DISCOVERY (2012)

Add to Collection

Article Oncology

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

C. Bokemeyer et al.

ANNALS OF ONCOLOGY (2011)

Add to Collection

Article Oncology

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer

Kristen M. Drescher et al.

FAMILIAL CANCER (2009)

Add to Collection

Article Oncology

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Carsten Bokemeyer et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Editorial Material Cell Biology

Mouse xenograft models vs GEM models for human cancer therapeutics

Ann Richmond et al.

DISEASE MODELS & MECHANISMS (2008)

Add to Collection

Article Medicine, General & Internal

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

Christos S. Karapetis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

Cetuximab for the treatment of colorectal cancer

Derek J. Jonker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Gastroenterology & Hepatology

Debunking dogma: Surgery for four or more colorectal liver metastases is justified

TM Pawlik et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2006)

Add to Collection

Review Oncology

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

JP Spano et al.

ANNALS OF ONCOLOGY (2005)

Add to Collection

Article Medicine, General & Internal

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

D Cunningham et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Gastroenterology & Hepatology

Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha

JL Yang et al.

GUT (2004)

Add to Collection

Article Oncology

Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer:: A tissue microarray study

MB Resnick et al.

CLINICAL CANCER RESEARCH (2004)

Add to Collection

Article Oncology

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

JA McKay et al.

EUROPEAN JOURNAL OF CANCER (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.